# Zydus share price today (Zydus Lifesciences Ltd, NSE: ZYDUSLIFE)

> Zydus share price today: ₹1,240.60 at the NSE close on 3 November 2026, up 27.3% in a year. Zydus Lifesciences (NSE: ZYDUSLIFE) is worth ₹1,23,701 crore, trades at a P/E of 25.4 and has closed between ₹864.25 and ₹1,245.50 over the past 52 weeks. > Zydus Lifesciences Ltd is reporting record margins. ZYDUSLIFE · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: ₹1,240.60 (+27.3% in a year)
- P/E: 25.4× (higher than 72% of the last 11 years)
- Revenue (Jun 2026): ₹8,017 Cr (+22.0% on a year ago)
- Profit (Jun 2026): ₹990 Cr (−34.9% on a year ago)
- Operating margin: 24.0% (−8.0 points on a year ago)
- ROCE: 21%, FY26
- ROIC: 10.8%, against a 12.0% cost of capital: −1.2 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Zydus share price today? Zydus Lifesciences Ltd's share price was ₹1,240.60 at the close on 3 November 2026. It has been rising for 23 weeks. That is 16.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹864 and ₹1,246, and at that close it sat 99% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 12 weeks in a row. Over the last 11 years the share price moved +260% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Zydus this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), lowest operating margin in 10 quarters and indian funds and insurers (DIIs) raised their stake for 4 quarters in a row. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹8,017 crore, +22% on a year earlier. Why: Revenue rose because international formulations grew 34%, led by demand across markets and focused execution. Next results: check whether India and Consumer Wellness growth can make up for slower international and US growth. From the earnings call on 11 Aug 2026. 2. Lowest operating margin in 10 quarters Operating margin was 24% in the June 2026 quarter, against 32% a year earlier. Why: The margin fell because the Mirabegron settlement cost more under the innovator deal. Next results: check whether the margin stays near 24% as Saroglitazar spending and acquisition costs hit expenses. From the earnings call on 11 Aug 2026. 3. Indian funds and insurers (DIIs) raised their stake for 4 quarters in a row From 10.9% to 11.3% of the company by the September 2026 quarter. ## What are Zydus' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Zydus reported revenue of ₹8,017 crore, up 22.0% from ₹6,574 crore a year earlier, and a profit of ₹990 crore, down 34.9% from ₹1,521 crore. ### Zydus results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹8,017 crore | ₹6,574 crore | +22.0% |
| Profit | ₹990 crore | ₹1,521 crore | −34.9% |
| Earnings per share | ₹9.42 | ₹14.58 | −35.4% |
| Operating margin | 24.0% | 32.0% | −8.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Zydus' management discussed these results on a call held on 11 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Zydus share price history? Zydus closed at ₹1,240.60 on 3 November 2026, up 27.3% from ₹974.45 a year earlier (31 October 2025) and up 152.3% over five years. Its highest weekly close since March 2016 was ₹1,300.90 on 9 August 2024. ### Zydus share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,129.40 | +9.8% |
| 1 month ago · 1 Oct 2026 | ₹1,145.70 | +8.3% |
| 6 months ago · 30 Apr 2026 | ₹891.90 | +39.1% |
| 1 year ago · 31 Oct 2025 | ₹974.45 | +27.3% |
| 3 years ago · 3 Nov 2023 | ₹584.85 | +112.1% |
| 5 years ago · 4 Nov 2021 | ₹491.75 | +152.3% |
| 10 years ago · 4 Nov 2016 | ₹390.00 | +218.1% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹344.65 | +260.0% |
| Highest weekly close since March 2016 · 9 Aug 2024 | ₹1,300.90 | −4.6% |
| Lowest weekly close since March 2016 · 16 Aug 2019 | ₹217.75 | +469.7% |
| 52-week high (weekly close) · 30 Oct 2026 | ₹1,245.50 | −0.4% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹864.25 | +43.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (565 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Zydus? 3 Nov 2026: Zydus closed at ₹1,240.60, up 9.8% on the week and up 8.3% on the month. Our read, 22 Aug 2026: April to June 2026 revenue rose 22.0% on a year earlier to ₹8,017 crore, but profit fell 34.9% on a year earlier to ₹990 crore and operating margin was 24%, versus 32% a year earlier. India branded formulations grew 20% on a year earlier and international formulations grew 34% on a year earlier, but management reduced its FY27 international-markets outlook to around single digits. ### Earlier

- 11 Aug 2026: Zydus held its results call for April to June 2026. Management guided: FY27 revenue framework: consolidated strong double-digit growth; India formulations mid-teens, 300-500 basis points ahead of market; international markets and US around single-digit; Consumer Wellness and Comfort Click double-digit. - 24 Jul 2026: ex-date for a dividend of ₹1 a share. - Results for April to June 2026: Revenue up 22.0% and profit down 34.9% on a year earlier. ### Our read of the business

April to June 2026 revenue rose 22.0% on a year earlier to ₹8,017 crore, but profit fell 34.9% on a year earlier to ₹990 crore and operating margin was 24%, versus 32% a year earlier. India branded formulations grew 20% on a year earlier and international formulations grew 34% on a year earlier, but management reduced its FY27 international-markets outlook to around single digits. April to June 2026: Revenue Growth Continues While profit Falls Against April to June 2025. (Our read after the April to June 2026 results, written 22 August 2026.)

## What dividend does Zydus pay? Zydus paid ₹1 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.08% at the ₹1,240.60 close on 3 November 2026. The last was a dividend of ₹1 a share, ex-date 24 July 2026. ### Zydus dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 24 Jul 2026 | ₹1 | Dividend | same day |
| 25 Jul 2025 | ₹11 | Dividend | same day |
| 26 Jul 2024 | ₹3 | Dividend | same day |
| 28 Jul 2023 | ₹6 | Dividend | same day |
| 28 Jul 2022 | ₹2.50 | Dividend | 29 Jul 2022 |
| 28 Jul 2021 | ₹3.50 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Zydus Lifesciences Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Zydus management say on the latest results call? On the call for April to June 2026, held on 11 August 2026, Zydus' management guided: FY27 revenue framework: consolidated strong double-digit growth; India formulations mid-teens, 300-500 basis points ahead of market; international markets and US around single-digit; Consumer Wellness and Comfort Click double-digit. > “With our branded business continuing to gain scale across markets, we expect its share to exceed two-thirds of our overall revenue over the medium term.”
> Dr. Sharvil Patel, on the call for April to June 2026

### What management guided

- FY27 operating margin around 24%; other expenses ₹1,900-2,000 crore per quarter excluding R&D; Mirabegron licensing amortization continues through July to September 2027. - FY27 capital spending ₹1,500-1,600 crore. - Saroglitazar planned for FY28 launch; opportunity $200-300 million conservatively and $400+ million optimistically. - 505(b)(2) share expected to exceed 15% by year-end; Assertio contribution begins next quarter at $15-20 million quarterly annualized run-rate; 30-40 US launches planned, including specialty. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4331/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 11 August 2026.)

## What is the future of Zydus? What is changing in the business? What is changing at Zydus, from the latest results and calls: india branded formulations and chronic mix, us specialty and biosimilars pivot and saroglitazar and china desidustat pipeline. - India Branded Formulations and Chronic Mix. India branded formulations grew 20% on a year earlier in April to June 2026 and chronic and sub-chronic share reached 54.2%. ✓ fact
- Saroglitazar and China Desidustat Pipeline. Saroglitazar PBC has priority review and is planned for FY28 launch, while Desidustat China access requires another two to three quarters. ✓ fact
- Consumer Wellness and MedTech Platform. Consumer Wellness grew 67% on a year earlier to ₹14.3 billion in April to June 2026; MedTech revenue was ₹2.8 billion. ✓ fact

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the April to June 2026 results, written 22 August 2026.)

## What could change the Zydus story? What are the risks? India branded formulations growth below 10% on a year earlier together with consolidated operating margin below 22% for two consecutive quarters, or a Complete Response Letter for Saroglitazar PBC that removes the FY28 commercialization path. ### Each change stops working if

- US Specialty and Biosimilars Pivot: Specialty market access is delayed or generic price erosion accelerates faster than new launches can offset it. - Saroglitazar and China Desidustat Pipeline: Saroglitazar receives a Complete Response Letter or China reimbursement access does not support commercialization. ### The main risks

- US Generic Cliff and Mirabegron Competition: Revlimid erosion and Mirabegron competition underpin the FY27 margin reset and single-digit US growth outlook. ✓ fact
- Margin and Cost Reset Persists: April to June 2026 operating margin was 24% and depreciation was ₹555 crore, while other expenses are guided at ₹1,900-2,000 Cr per quarter excluding R&D. ✓ fact
- Guidance Reductions and Communication Risk: The August consistency review identifies four changed expectations, not a stable forward framework. ✓ fact
- Working-Capital Absorption and Free-Cash-Flow Risk: FY26 operating cash flow was ₹2,117 crore versus ₹5,124 crore profit; cash decomposition shows inventory-led working-capital expansion and ₹13,386 crore capital spending. ✓ fact

(Our read after the April to June 2026 results, written 22 August 2026.)

## What to watch in Zydus' next results? When Zydus reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Assertio contribution begins next quarter; check acquired-product revenue, launch execution and specialty mix. - What to check (from the call)
- Assertio contribution begins next quarter; check acquired-product revenue, launch execution and specialty mix. - check whether margin remains within the maintained framework. - China Desidustat reimbursement and NRDL access progress; check movement from approval and API supply toward commercialization. - US biosimilar and specialty launches continue; check NUFYMCO traction and broader product uptake. ## Which stock lists is Zydus on? Zydus is on 3 of our India lists: Momentum stocks, 52 week high & low and Pharma stocks. - [Momentum stocks Market cap cr: 123740.24849458049](https://www.sectoralpha.in/momentum-stocks-india)
- [52 week high & low 52-week position: At 52-week high](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Pharma stocks Market value (₹ crore): 123740.24849458049](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Zydus profitable? Zydus Lifesciences Ltd earned ₹990 Cr of net profit in the Jun 2026 quarter, −34.9% on the same quarter a year earlier. Full-year FY26 profit was ₹5,124 Cr. Over 10 years profit has grown 10.1% a year on average. That is 12.3% of the quarter's revenue. The same quarter a year earlier earned ₹1,521 Cr. For the full year, FY26 profit was ₹5,124 Cr (+9.7% on the year before). Why profit moved: revenue changed +22.0% on a year earlier and the margin moved −8.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +1.8% and revenue +21.4%. Profit is growing slower than sales: rising costs are taking part of the growth. FY26-Q4. revenue ₹7,587 Cr and profit ₹1,341 Cr as reported. FY27-Q1. revenue ₹8,017 Cr and profit ₹990 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much revenue does Zydus make, and is it growing? Zydus Lifesciences Ltd reported ₹8,017 Cr of revenue in the Jun 2026 quarter, +22.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 11.2% a year on average. The last full year, FY26, came in at ₹27,148 Cr. Why this happened. Consumer Wellness revenue was Rs 14.3 billion, up 67% YoY, with the international portfolio up 25% like-for-like and domestic business up 5%. MedTech revenue was Rs 2.8 billion across orthopedics, cardiology, and nephrology. The last four reported quarters add to ₹28,591 Cr. FY26 revenue was ₹27,148 Cr, +16.8% on the year before. Recent pace: the last four quarters grew +21.4% on average, against 11.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +21.1%, against +17.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −2.5%, against +3.1% a year (rolling over). FY26-Q4. revenue ₹7,587 Cr and profit ₹1,341 Cr as reported. FY27-Q1. revenue ₹8,017 Cr and profit ₹990 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Zydus keep? Zydus Lifesciences Ltd's operating margin was 24.0% in the Jun 2026 quarter, 8.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 17.0% and 31.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −7.7 percentage points on the year while gross margin changed −0.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. FY26-Q4. revenue ₹7,587 Cr and profit ₹1,341 Cr as reported. FY27-Q1. revenue ₹8,017 Cr and profit ₹990 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## Is Zydus' profit turning into cash? Over the last 3 years, 88% of Zydus Lifesciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹2,117 Cr of operating cash against ₹5,124 Cr of profit. After ₹13,386 Cr of spending on assets, free cash was −₹11,269 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 88% of profit came in as cash: the cash cycle got 54 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 5.9× depreciation over three years. The next section checks what that spending is building. ## Where does Zydus' cash go? Zydus Lifesciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 212 days in FY26, up from 158 days in FY21. It spent ₹18,170 Cr on assets over the last 3 years. Customers take 73 days to pay, and stock sits for 282 days on average. At FY26 sales of ₹27,148 Cr, each day of that cycle ties up about ₹74.4 Cr, so roughly ₹15,768 Cr is tied up in the business at any time. FY26: customers took 73 days to pay and stock sat for 282 days, about 9.3 months of sales sitting as stock, for a full cycle of 212 days, longer than FY21's 158. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 282 days. Customers pay about 73 days after that. Suppliers are paid at 142 days. Together that makes the 212-day cycle. Spending on assets: ₹18,170 Cr over the last 3 years, against ₹3,088 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3,698 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Zydus' P/E ratio, and how does it compare with its own history? Zydus Lifesciences Ltd's P/E is 25.4×, near the high end of its own history: higher than 72% of past readings. Its usual P/E (the middle reading) is 21.9×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹44.94. Why the multiple is where it is: over the past year earnings per share moved +11.4% while the price moved +27.3%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +20.3% a year; about +14.8% a year came from earnings growth and about +5.5 percentage points from the multiple (the market paying more); over 10 years the price moved +12.3% a year; about +10.9% a year came from earnings growth and about +1.4 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Zydus share price assume? Worked out from its price on 24 August 2026, Zydus Lifesciences Ltd's share price assumed profit growth of about 13.9% a year. Over the past 10 years its profit actually grew 10.1% a year. Today its P/E is 25.4×, higher than 72% of its own last 11 years. This is a one-day reading, taken on 24 August 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Zydus business getting better or worse? Zydus Lifesciences Ltd's business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +63.3% at its peak to −2.5% now), while ROCE is still 20.1%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## What is the Zydus story, and has it been checked? Zydus Lifesciences Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: CONTRACTION. Our read, 22 August 2026. From the numbers. Deterministic normalization is the governing cycle verdict: operating cycle is…

From the price. Price stage 2, week 23, above its 200-day line, relative strength rising. From the research. Where they disagree. The surface read therefore does not support low or trough language. What is proven. What is not proven yet. India branded formulations growth below 10% YoY together with consolidated EBITDA margin below 22% for two consecutive quarters, or a Complete Response Letter for Saroglitazar PBC that removes the FY28 commercialization path. What would change our mind. India branded formulations growth below 10% YoY together with consolidated EBITDA margin below 22% for two consecutive quarters, or a Complete Response Letter for Saroglitazar PBC that removes the FY28 commercialization path. The test written in advance. India branded formulations growth below 10% YoY together with consolidated EBITDA margin below 22% for two consecutive quarters, or a Complete Response Letter for Saroglitazar PBC that removes the FY28 commercialization path. Measured by: the thesis as written as stated by the next result. The test written in advance. US Generic Cliff and Mirabegron Competition. Measured by: US Generic Cliff and Mirabegron Competition North America revenue and consolidated EBITDA margin against the Q1 FY27 baseline. by the next result. The test written in advance. Margin and Cost Reset Persists. Measured by: Margin and Cost Reset Persists Quarterly EBITDA margin at or above 24%. by the next result. What the company does. Q1 FY27 revenue rose 22.0% YoY to Rs 8,017 Cr, but PAT fell 34.9% YoY to Rs 990 Cr and OPM was 24%, versus 32% a year earlier. India branded formulations grew 20% YoY and international formulations grew 34% YoY, but management reduced its FY27 international-markets outlook to around single digits. What the surface reading misses. The surface reading is: FY26 revenue grew 16.8% YoY. The research reads it further: The revenue result establishes a high FY26 comparison base; it does not prove that FY27 profit conversion or segment growth will persist. What the surface reading misses. The surface reading is: FY26 PAT increased 9.7% YoY. The research reads it further: PAT grew slower than revenue and precedes the Q1 FY27 PAT decline, so FY26 profit cannot be extrapolated mechanically. Lever 2 · Value-added mix: building. India branded formulations grew 20% YoY in Q1 FY27 and chronic and sub-chronic share reached 54.2%. What proves it keeps working: India Branded Formulations and Chronic Mix. It stops working if India formulations growth falls below market growth or the branded portfolio loses price realization. Lever 12 · New product launch: building. Saroglitazar PBC has priority review and is planned for FY28 launch, while Desidustat China access requires another two to three quarters. What proves it keeps working: Saroglitazar and China Desidustat Pipeline. It stops working if Saroglitazar receives a Complete Response Letter or China reimbursement access does not support commercialization. Sources: our stock research file (22 August 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Zydus management deliver what it promised? What Zydus Lifesciences Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. International Markets Growth Outlook Reduced · 11 August 2026. Management's international markets outlook has materially deteriorated without an explanation. In May 2026, management cited 40% plus annual growth and said momentum would continue in the current year, while in Aug 2026 it guided international markets to around single-digit growth; Feb 2026 had also indicated 20% plus growth continuing in the near future. Vaccine Business Ambition Reduced · 11 August 2026. Management's stated vaccine ambition is materially lower in Aug 2026 than in Feb 2026. Feb planned a 1,000 crore-plus business over the next 3 to 4 years, whereas Aug described a 300 to 400 crore goal and did not explain whether this replaced or narrowed the earlier ambition. US Launch Plan Reduced · 11 August 2026. US launch expectations have been reduced in Aug 2026 without an explanation. May 2026 called for 40 to 45-plus FY27 launches, while the latest call gave a range of 30 to 40 and at least 30-plus launches, implying a materially lower plan. Desidustat China Commercialization Timeline Less Certain · 11 August 2026. Desidustat's China commercialization timeline now appears later and less certain than previously indicated. Feb 2026 management hoped for a Q2 FY27 launch, but Aug 2026 said another 2-3 quarters were needed for approvals and access through the reimbursement list, without reconciling the changed timing. Every quote above is taken word for word from the company’s own earnings calls. ## What is Zydus management's track record? Capital allocation sound through cycle (net debt/operating profit 0.5x, Comfort Click accretive); Assertio pivot to oncology supportive care away from stated gastro/CNS priorities is the credibility monitor. ### Regulatory and governance record

Halol FDA Warning Letter (Aug-2024) closed Dec-2025; Reg-29 ₹11,800 penalties inadvertent/remediated; no SEBI/CBI/ED action or fraud. A fresh FDA Warning Letter for the Jarod injectables unit (12/09/2025) is the new monitor item. 0% Promoter shares pledged

Sources:

- [trendlyne.com](https://trendlyne.com/research-reports/stock/229/ZYDUSLIFE/zydus-lifesciences-ltd/)
- [fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zydus-lifesciences-limited-685224-12092025-0)
- [indmoney.com](https://www.indmoney.com/stocks/zydus-lifesciences-ltd-share-price)

(Checked 30 June 2026.)

## How much does Zydus earn on its capital? Zydus Lifesciences Ltd earned a ROCE of 21% in FY26. That is up from a low of 11% in FY20. Its return on capital used (ROIC) is 1.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 18.9% net margin and 0.54× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 18.9% net margin × 0.54× asset turnover × 1.87× leverage (assets divided by equity) ≈ 19.1% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 10.8% − 12.0% = −1.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 10.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 14.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Zydus have too much debt? Zydus Lifesciences Ltd has total debt of ₹12,515 Cr against shareholder equity of ₹29,582 Cr as of Jun 2026, so its debt is 0.42× its equity. Year by year, that ratio went from 0.22 in FY22 to 0.42 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Zydus shareholding pattern? No group of Zydus Lifesciences Ltd's owners changed its stake by a full percentage point over the last two years. Foreign institutions moved −0.5 points over the same period, to 7.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +0.7 points over 8 quarters, to 11.3%; Foreign institutions: −0.5 points over 8 quarters, to 7.0%; Promoters: +0.0 points over 8 quarters, to 75.0%. ## How far is Zydus from balance-sheet trouble? For Zydus Lifesciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Zydus rank in its industry? 58.1 out of 100, rank 15 of 44 in Pharma - Formulators, with 96% of the evidence available. Zydus Lifesciences Ltd scores 58.1 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 15. Relative strength against the index is 28.8%, and revenue and profit growth are weak. The four parts add up to the total exactly: 11.9 + 16.5 + 12.1 + 17.6 = 58.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Zydus compared with? Zydus ranks 15 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 58.1 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. Zydus Lifesciences Ltd this page ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.9/35 · Revenue 21.1% · Profit -2.5% · Operating margin change -8 points · 88% evidence Capital efficiency 16.5/25 · ROCE 21.1% · Operating margin 24% · 100% evidence Valuation 12.1/20 · P/E 25.5× · PEG 1.22 · 100% evidence Relative strength 17.6/20 · Lead over its industry 3.5% · Lead over NIFTY 500 28.8% · 1 year 27.8% · 100% evidence · 7 of 12 weeks ahead Exact sum: 11.9 + 16.5 + 12.1 + 17.6 = 58.1 · What this means: Relative strength against the index is 28.8%, and revenue and profit growth are weak. 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Zydus in size? Zydus is the 3rd largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sun Pharmaceutical Industries and Torrent Pharmaceuticals. Just below it: Dr Reddys Laboratories, Cipla, Mankind Pharma and Aurobindo Pharma. ### Pharma - Formulators companies close in size

1. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) ₹4,26,530 crore
2. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) ₹1,75,479 crore
3. Zydus Lifesciences Ltd ₹1,24,239 crore
4. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) ₹1,12,849 crore
5. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) ₹1,11,397 crore
6. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) ₹1,02,964 crore
7. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) ₹96,744 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [CG Power & Industrial Solutions Ltd](https://www.sectoralpha.in/stocks/cg-power-industrial-solutions-ltd) ₹1,26,668 crore · Capital Goods - Transformers
2. [LTM Ltd](https://www.sectoralpha.in/stocks/ltm-ltd) ₹1,25,583 crore · IT - Software
3. Zydus Lifesciences Ltd ₹1,24,239 crore
4. [Bharat Petroleum Corporation Ltd](https://www.sectoralpha.in/stocks/bharat-petroleum-corporation-ltd) ₹1,23,604 crore · Refineries
5. [Cummins India Ltd](https://www.sectoralpha.in/stocks/cummins-india-ltd) ₹1,23,426 crore · Gensets

## What else do people ask about Zydus? ### What is Zydus's share price today? Zydus Lifesciences Ltd's share price is ₹1,240.60, +27.3% over the past year. The whole company is worth ₹1,23,701 Cr on the market. In the last 52 weeks it traded between ₹864 to ₹1,246; today it is 99% of the way up from the low, 16.0% above its 200-day average (as of 3 November 2026). ### What were Zydus's latest quarterly results? Zydus Lifesciences Ltd reported revenue of ₹8,017 Cr and net profit of ₹990 Cr for the Jun 2026 quarter. Revenue rose 22.0% and profit fell 34.9% compared with a year earlier. Earnings per share were ₹9.42. The operating margin was 24.0%, 8.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Zydus's market cap? Zydus Lifesciences Ltd's market capitalisation is ₹1,23,701 Cr at a share price of ₹1,240.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Zydus performing? Zydus Lifesciences Ltd's share price has been rising for 23 weeks. In its latest quarter, revenue rose 22.0% and profit fell 34.9% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 12 weeks running (as of 3 November 2026). ### Will Zydus's share price go up? This page does not forecast Zydus Lifesciences Ltd's share price. What it shows instead: the share price is ₹1,240.60, and it has been rising for 23 weeks. Its P/E of 25.4× is higher than 72% of its own last 11 years (as of 3 November 2026). ### Who owns Zydus? Promoters own 75.0% of Zydus Lifesciences Ltd, foreign institutions 7.0%, domestic institutions 11.3% and the public 6.7% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Does Zydus have too much debt? Zydus Lifesciences Ltd has a moderate amount of debt: its debt is 0.46× its equity, and its operating profit is 19 times its interest bill. FY26 borrowings were ₹12,496 Cr against equity of ₹27,112 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Zydus in its business cycle? Zydus Lifesciences Ltd's FY26 operating margin was 31.0%, against a 13-year range of 17.0% to 31.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 24.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Zydus story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Zydus a stock worth studying right now? What the numbers show: Zydus Lifesciences Ltd is reporting record margins. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Zydus share price forecast for 2026? What management itself guided: FY27 revenue framework: consolidated strong double-digit growth; India formulations mid-teens, 300-500 basis points ahead of market; international markets and US around single-digit; Consumer Wellness and Comfort Click double-digit. What is changing at Zydus, from the latest results and calls: india branded formulations and chronic mix, us specialty and biosimilars pivot and saroglitazar and china desidustat pipeline. What would change the story: India branded formulations growth below 10% on a year earlier together with consolidated operating margin below 22% for two consecutive quarters, or a Complete Response Letter for Saroglitazar PBC that removes the FY28 commercialization path. ### Where does this page get Zydus' management information? From Zydus' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.